Related Experiment Video
Updated: Jul 20, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
High BRAF mutation frequency does not characterize all melanocytic tumor types
Gerald Saldanha1, David Purnell, Alan Fletcher
1Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom. gss4@le.ac.uk
Abstract:
Cutaneous melanoma (CM) is the most lethal form of skin cancer. Along with some benign melanocytic tumors, the majority shows BRAF or NRAS mutation, but it is not known whether these are essential to all forms of melanocytic neoplasia. We screened 79 melanocytic tumors of different types for BRAF and NRAS mutations and looked at MAPK pathway activity using immunohistochemistry in a subset. Significant differences in BRAF exon 15 mutation frequency were found: 14/16 (87.5%) in common acquired naevi (CANs), 9/12 (75%) in CMs, 0/26 in Spitz naevi and 3/25 (12%) in blue naevi (p < 0.01). We looked at whether Spitz and blue naevi showed a compensatory increase in BRAF exon 11 and/or NRAS exons 1 and 2 mutations to account for the low BRAF exon 15 mutation frequency. NRAS mutations were found in only 1/16 (6.3%) Spitz naevi and 0/15 blue naevi. In addition, NRAS mutations were found in 2/11 (18.2%) CANs and 3/12 (25%) CMs. None of the tumors showed BRAF exon 11 mutations. Despite their low combined BRAF and NRAS mutation frequency, Spitz naevi showed strong MAPK pathway activation as measured by cytoplasmic expression of dually phosphorylated ERK1/2, while blue naevi had weak pathway activation. We conclude that BRAF and NRAS mutations are not necessary for melanocytic tumor development and that some types of tumor must arise by alternative mechanisms.
Insights
BRAF and NRAS mutations are common in many melanocytic tumors but not essential for all types. Some skin cancers and benign nevi develop through alternative pathways, highlighting diverse mechanisms in melanocytic neoplasia.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Cutaneous melanoma (CM) is a lethal skin cancer.
- BRAF and NRAS mutations are frequently observed in CM and some benign melanocytic tumors.
- The necessity of these mutations for all melanocytic neoplasia remains unclear.
Purpose of the Study:
- To investigate the frequency of BRAF and NRAS mutations across various melanocytic tumor types.
- To assess the activity of the MAPK pathway in tumors with low BRAF/NRAS mutation rates.
- To determine if BRAF/NRAS mutations are essential for melanocytic tumor development.
Main Methods:
- Screening of 79 melanocytic tumors for BRAF and NRAS mutations.
- Immunohistochemistry analysis of MAPK pathway activation (phosphorylated ERK1/2) in a subset of tumors.
- Statistical analysis to compare mutation frequencies across different tumor types.
Main Results:
- Significant differences in BRAF exon 15 mutation frequency were observed: high in common acquired nevi (87.5%) and CMs (75%), but absent in Spitz nevi and low in blue nevi (12%).
- NRAS mutations were infrequent across all tumor types studied.
- Spitz nevi exhibited strong MAPK pathway activation despite low BRAF/NRAS mutation rates, while blue nevi showed weak activation.
Conclusions:
- BRAF and NRAS mutations are not universally required for the development of all melanocytic tumors.
- Spitz nevi and potentially other tumor types may arise through alternative molecular mechanisms.
- Understanding these alternative pathways is crucial for comprehensive diagnosis and treatment of melanocytic neoplasia.
More Related Videos
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Related Concept Videos
Abnormal Proliferation
Cancers Originate from Somatic Mutations in a Single Cell
The Ras Gene
Ras is a superfamily...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancers Originate from Somatic Mutations in a Single Cell
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...